Plain-English translation of NCT07013474 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a new antiviral medication called can help treat COVID-19 in people with severely weakened immune systems. Researchers will compare this medication alone, this medication combined with another antiviral drug called , and alone. The goal is to see if the new treatment is safe and more effective at helping immunocompromised patients recover from COVID-19.
People with severely weakened immune systems struggle to fight off COVID-19 on their own and are at high risk for long-lasting or worsening infections. This trial exists to find out whether this new antiviral medication might help protect this vulnerable group better than current treatments alone.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive one of three treatments: the new medication by mouth twice daily, the new medication by mouth twice daily plus an IV infusion of daily, or by IV daily alone (with placebo pills that look like the medication but contain no drug). You will visit the study clinic about 10 times over 24 weeks for blood work, nasal swabs (some collected at home), and questionnaires to help researchers track how you're doing.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States